Taejong Song
Sungkyunkwan University · 医学
研究室紹介
Professor Taejong Song's research lab specializes in gynecological oncology and reproductive health, with a strong focus on improving surgical outcomes and preserving fertility and ovarian function in women with gynecological conditions. The lab investigates minimally invasive surgical techniques, including the use of hemostatic sealants and opportunistic salpingectomy, to minimize damage to ovarian reserve and enhance long-term reproductive and oncological outcomes. Key research directions include the impact of medical therapies—such as ACEIs/ARBs—on cancer recurrence, and the clinical efficacy of devices like the LNG-IUS in managing adenomyosis and menorrhagia.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15To assess the current evidence on the potential benefit of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on cancer recurrence and survival, we comprehensively searched PubMed, Embase, and the Cochrane Library from their inception to April 2013. Two authors screened out duplicates and independently reviewed the eligibility of each study. We included comparative studies comparing the use and nonuse of ACEIs or ARBs in cancer patients. Primary outcomes wer
OBJECTIVE: The objective of this study was to evaluate the clinical aspects of the levonorgestrel-releasing intrauterine system (LNG-IUS) in patients with large adenomyosis associated with dysmenorrhea and/or heavy menstrual bleeding (HMB). MATERIALS AND METHODS: Data were collected retrospectively from 48 patients with large adenomyosis (gestational age ≥ 12 weeks during pelvic examination) diagnosed via transvaginal ultrasonography between January 2008 and December 2009. Clinical outcomes, inc
BACKGROUND: The aim of this study was to compare the oncologic and reproductive outcomes of patients with borderline ovarian tumours (BOTs) who were treated with cystectomy or unilateral salpingo-oophorectomy (USO). METHODS: The medical records of patients with BOTs who were treated between 1997 and 2009 were reviewed retrospectively. The recurrence rates were compared between the USO and cystectomy groups. The reproductive outcomes were assessed by telephone interviews. RESULTS: Patients with B
STUDY QUESTION: Is hemostasis by hemostatic sealant superior to that achieved by bipolar coagulation in preserving ovarian reserve in patients undergoing laparoscopic ovarian cystectomy? SUMMARY ANSWER: Post-operative ovarian reserve, determined by serial serum anti-Müllerian hormone (AMH) levels, was significantly less diminished after ovarian hemostasis when hemostatic sealant was used rather than bipolar coagulation. WHAT IS KNOWN ALREADY: Hemostasis achieved with bipolar coagulation at ovari
The RT and RH groups, unlike the CC group, had compromised sexual function after the treatment of early-stage cervical cancer.
OBJECTIVE: The aim of the study was to investigate whether opportunistic salpingectomy has any deleterious effects on ovarian reserve and increases surgical risk in patients undergoing laparoscopic hysterectomy. DESIGN: A multicentre, randomised controlled trial. SETTING: Three university hospitals in Korea. POPULATION: Sixty-eight patients undergoing laparoscopic hysterectomy for the treatment of symptomatic benign uterine diseases. METHODS: Patients were randomised to undergo either opportunis
Significant geographic variation is evident among BOT histology in different parts of the world. More research is needed to understand this phenomenon.
STUDY QUESTION: Can a two-dose methotrexate treatment protocol improve the treatment success rate compared with a single-dose protocol in women with an ectopic pregnancy? SUMMARY ANSWER: The two-dose protocol was not superior to the single-dose protocol for the treatment of ectopic pregnancy. WHAT IS KNOWN ALREADY: Although the two-dose methotrexate protocol for ectopic pregnancy was recently introduced to combine the efficacy and convenience of the fixed multi-dose and single-dose protocols, st